

*Jpw* 1643



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In Application of:

Robertson, et al.

Serial No. 10/534,773

**Filed: May 13, 2005**

**For: TUMOUR MARKER PROTEINS  
AND USES THEREOF**

Art Unit: 1643

**Examiner: Lynn Anne Bristol**

## INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

The citation of information on the attached Form PTO/SB/08 is made pursuant to 37 C.F.R. §§ 1.56, 1.97, and 1.98. Copies of the non-US patent references are enclosed.

As this Information Disclosure Statement is being filed before the mailing of a first Office Action on the merits, no fees are believed due. The Commissioner, however, is hereby authorized to charge any deficiency to Deposit Account 11-0855 if a fee is due.


The citation of this information does not constitute an admission of priority or that any cited item is available as a reference, or a waiver of any right the applicant may have under applicable statutes, Rules of Practice in patent cases, or otherwise.

I hereby certify that this correspondence is being deposited with the United States Postal Service via First Class Mail addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on December 11, 2006.

U, Alexandria, VA 22313-1450 on Dec 1991  
 Wesley Andrew  
 Wesley Andrew

*Information Disclosure Statement*  
*U.S. Application Serial No. 10/534,773*


Respectfully submitted,

A handwritten signature in black ink, appearing to read 'J. L. Greene', with a stylized flourish at the end.

Jamie L. Greene  
Reg. No. 32,467

December 11, 2006

KILPATRICK STOCKTON LLP  
Suite 2800, 1100 Peachtree Street  
Atlanta, Georgia 30309  
(404) 815-6500  
Our Docket: 49409-0050 (315804)



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<b>Substitute for Form 1449/A/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	10/534,773
		Filing Date	May 13, 2005
		First Named Inventor	Robertson
		Group Art Unit	1643
		Examiner Name	Lynn Anne Bristol
Sheet 1	of 5	Attorney Docket Number	49409-0050 (315804)

**U.S. PATENT DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
	1	US-4,898,951		Symons	02-06-1990	
	2	US-4,937,185		Webb et al.	06-26-1990	
	3	US-5,157,020		Kay et al.	10-20-1992	
	4	US-5,652,115		Marks et al.	07-26-1990	
	5	US-5,726,023		Cheever et al.	03-10-1998	
	6	US-5,876,728		Kass et al.	03-02-1999	
	7	US-6,322,989		Cohen	11-27-2001	
	8	US 20020168696		Hanash	11-14-2002	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	7 <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
	9		EP 0 236 606		Imre Corporation	06-24-1992		
	10		JP 09 189702		Hitachi Chem Co. Ltd.	07-22-1997		
	11		WO 92/13065		Novo Nordisk A/S	08-06-1992		
	12		WO 93/11236		Medical Research Council	06-10-1993		
	13		WO 93/21529		Marks et al.	10-1993		
	14		WO 94/23728		Northwestern University	10-27-1994		
	15		WO 96/00084		Torchilin et al.	01-04-1996		
	16		WO 96/03502 A2		Ramot University Authority for Applied Research and Industrial Development Ltd.	02-08-1996		
	17		WO 97/14794		Lane et al.	04-24-1997		
	18		WO 00/26668		The Regents of the University of Michigan	05-11-2000		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	10/534,773
		Filing Date	May 13, 2005
		First Named Inventor	Robertson
		Group Art Unit	1643
		Examiner Name	Lynn Anne Bristol
Sheet 2	of 5	Attorney Docket Number	49409-0050 (315804)

OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	19	APARECIDA et al., "Value of CEA Level Determination in Gallbladder Bile in the Diagnosis of Liver Metastases Secondary to Colorectal Adenocarcinoma", Sao Paulo Medical Journal, 2001, Volume 119, No. 3, pp. 110-113.	
	20	APOSTOLOPOULOS et al., Nature Medicine, 1998, Vol. 4, pp. 315-320.	
	21	BAECHSTROM, et al., "Purification and Characterization of Sialyl-Le - Carrying Mucins of Human Bile; Evidence for the Presence of MUC1 and MUC3 Apoproteins", The Journal of Biological Chemistry, 1994, Volume 269, No. 20, pp. 14430-14437.	
	22	BEATTY, et al., "Biochemical Characterization of the Soluble Form of Tumor Antigen MUC1 Isolated from Sera and Ascites Fluid of Breast and Pancreatic Cancer Patients", Clinical Cancer Research, 2001, Vol. 7, pp. 781-787.	
	23	BEN-MAHREZ et al., British Journal of Cancer, 1988.	
	24	BHATTI et al.; Journal of Tumor Marker Oncology, Summer-1994, Vol. 9, pp. 125-131.	
	25	CROCE et al.; Cancer. Immunol. Immunother., 1995, Vol. 40, pp. 132-137.	
	26	DEGUCHI et al.; Int. Arch. Allergy Appl. Immunol., 1988, Vol. 87, pp. 313-316.	
	27	DENTON et al.; Cancer Letters, 1993, Vol. 70, pp. 143-150.	
	28	DISIS et al.; Journal of Clinical Oncology, 1997, Vol. 15, pp. 3363-3367.	
	29	FISHMAN, P., "Application of autoantibodies to cancer therapy: A new concept", <i>The 9<sup>th</sup> International Congress of Immunology</i> , 1995, p. 664.	
	30	GOUREVITCH, MM; "Polymorphic epithelial mucin (MUC-1)-containing circulating immune complexes in carcinoma patients"; <i>British Journal of Cancer</i> ; 72, pp. 934-938; (1995).	
	31	GREEN et al.; European Journal of Cancer, 1994, Vol. 30A, pp. 580-584.	
	32	GÜRE, "Human Lung Cancer Antigens Recognized by Autologous Antibodies Definition of a Novel cDNA Derived from the Tumor Suppressor Gene Locus on Chromosome 3p21.3", Ludwig Institute for Cancer Research, pp. 1034-1040	
	33	Abstract of HAYES; Anticancer Drugs, 1995, Vol. 6, suppl. 2, pp. 26-27.	
	34	HEHIR et al., Journal of Surgical Oncology, 1993, Vol. 54, pp. 207-210.	
	35	HILL et al., "Nature of Carcinoembryonic Antigen Purified From Malignant Ascitic Fluid of Serous Cystadenocarcinoma of the Ovary", Molecular Immunology, 1981, Vol. 18, No. 7, pp. 647-653.	
	36	HINODA, et al., "Detection of a Circulating Antibody Against a Peptide Epitope on a Mucin Core Protein, MUC1, in Ulcerative Colitis", 1991, pp. 163-168.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	10/534,773
		Filing Date	May 13, 2005
		First Named Inventor	Robertson
		Group Art Unit	1643
		Examiner Name	Lynn Anne Bristol
Sheet 3	of 5	Attorney Docket Number	49409-0050 (315804)

OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	37	HOUGHTON et al.; "Detection of Cell Surface and Intracellular Antigens by Human Monoclonal Antibodies – Hybrid Cell Lines Derived from Lymphocytes of Patients with Malignant Melanoma"; <i>J. Exp. Med.</i> ; Vol. 158, July 1983; pp. 53-65.	
	38	JANEWAY et al., Immunobiology, 5 <sup>th</sup> ed.	
	39	KARANIKAS, et al. J Clin Invest 1997 December 1, Vol. 100, No. 11, pp. 2783-2792.	
	40	KAWAHARA; Cancer, 1986, Vol. 58, pp. 2008-2012.	
	41	KOTERA et al.; Cancer Research, 1994, Vol. 54, pp. 2856-2860.	
	42	KURALAY, et al., "Diagnostic Usefulness of Tumour Marker Levels in Pleural Effusions of Malignant and Benign Origin, Clinica Chimica Acta, 2000, Vol. 300, pp. 43-55.	
	43	KUTTEH, W.H., et al., "Immunologic characterization of tumor markers in human ovarian cancer cell lines"; <i>Journal of the Society for Gynecologic Investigation</i> , 1996, vol. 3, no. 4, pp. 216-222.	
	44	LAENG, et al., "Anti-Neural Autoantibodies, types 1 and 2: Their Utility in the Study of Tumors of the Nervous System", <i>Acta Neuropathol</i> , 1998, Vol. 96, pp. 329-339.	
	45	LAFOND, R.E., et al., "Autoantibodies to c-myc protein: elevated levels in patients with African Burkitt's lymphoma and normal Ghanians", <i>Autoimmunity</i> , vol. 13, no. 3, 1992, pp. 215-224.	
	46	LAI, et al., "Presence of Serum Anti-P53 Antibodies is Associated with Pleural Effusions and Poor Prognosis in Lung Cancer Patients", <i>Clinical Cancer Research</i> , 1998, Vol. 4, pp. 3025-3030.	
	47	LAWNICZAK, et al., "The Search for Tumor-Associated Proteins in Pleural Effusions by Means of Monoclonal Antibodies and a Dot Blot Assay", <i>Lung</i> , 1992, Vol. 170, pp. 65-74.	
	48	MERCER, "Use of Multiple Markers to Enhance Clinical Utility", <i>Immunology Series</i> , Vol. 53, 1990, pp. 39-54.	
	49	MONTENARH, et al., "P53 Autoantibodies in the Sera, Cyst and Ascitic Fluids of Patients with Ovarian Cancer", <i>International Journal of Oncology</i> , 1998, Vol. 13, pp. 605-610.	
	50	NERY, et al., "Isolation and Partial Characterization of Macromolecular Urinary Aggregates Containing Carcinoembryonic Antigen-Like Activity", <i>Br J. Cancer</i> , 1974, Vol. 29, No. 413,	
	51	NUSTAD et al., "Epitopes on CA 125 from Cervical Mucus and Ascites Fluid and Characterization of Six New Antibodies", pp. 303-314.	
	52	Abstract of PANDHA et al.; <i>Cancer Gene Therapy</i> , 1997, Vol. 4, No. 5, page 310.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/APTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/534,773		
		Filing Date	May 13, 2005		
		First Named Inventor	Robertson		
		Group Art Unit	1643		
		Examiner Name	Lynn Anne Bristol		
Sheet	4	of	5	Attorney Docket Number	49409-0050 (315804)

OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	53	PAVELIC et al., Anticancer Research, 1991, Vol. 11, pp. 1421-1428.	
	54	PETRARCA, C., "Human Antibodies Against the Polymorphic Epithelial Mucin in Ovarian Cancer Patients Recognise a Novel Sequence in the Tandem Repeat Region"; <i>European Journal of Cancer</i> , Vol. 32A, No. 12, pp. 2155-2163, 1996.	
	55	PETRAKOU et al.; International Journal of oncology, 1997, Vol. 11, suppl. Page 902.	
	56	RAO, S.G., "Detection of Human Ovarian Tumor Associated Antigens by Autologous Antibodies Isolated from Ovarian Carcinoma Ascites Fluid"; <i>Proceedings of the American Association for Cancer Research Annual Meeting</i> , 1987, vol. 28, p. 358.	
	57	RUSCIANO, "Concomitant Purification of Prostatic Carcinoma Tumor Markers from Human Seminal Fluid Under Nondenaturing Conditions", <i>Clinical Chemistry</i> , 1988, Vol. 34, No. 12, pp. 2528-2532.	
	58	SAHIN et al.; PNAS, 1995, Vol. 92, pp. 11810-11813	
	59	SANDRIN et al., Glycoconjugate Journal, 1997, Vol. 14, pp. 97-105.	
	60	SCANLAN et al.; International Journal of Cancer, 1998, Vol. 76, pp. 652-658	
	61	SCHNEIDER, J. "P53 Protein, EGF Receptor, and Anti-P53 Antibodies in Serum from Patients with Occupationally Derived Lung Cancer", <i>British Journal of Cancer</i> , 1999, Vol. 80, No. 12, pp. 1987-1994.	
	62	SHIBATA, et al., "Purification and Characterization of Prostate Specific Antigen from Human Urine", <i>Biochimica et Biophysica Acta</i> , 1997, Vol. 1336, pp. 425-433.	
	63	SOKOLOFF, et al., "A Dual-Monoclonal Sandwich Assay for Prostate-Specific Membrane Antigen: Levels in Tissues, Seminal Fluid and Urine", <i>The Prostate</i> , 2000, Vol. 43, pp. 150-157.	
	64	Abstract of STEARNS et al.; <i>Breast Cancer Research and Treatment</i> , 8 Feb. 1998, Vol. 52, pp. 239-259	
	65	STUBBS, et al., "Faecal Carcinoembryonic Antigen (CEA) in Patients with Large Bowel Cancer", <i>European Journal of Surgical Oncology</i> , 1987, Vol. 13, pp. 433-436.	
	66	TONDINI, et al., "Comparison of CA15-3 and Carcinoembryonic Antigen in Monitoring the Clinical Course of Patients with Metastatic Breast Cancer", <i>Cancer Research</i> , 1988, Vol. 48, No. 14, pp. 4107-4112.	
	67	TOTH, et al., "A Carcinoembryonic Antigen (CEA) Binding Protein From Ascites Influences CEA Uptake by Macrophages", 1990, Vol. 171, No. 2, pp. 633-640.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	10/534,773
		Filing Date	May 13, 2005
		First Named Inventor	Robertson
		Group Art Unit	1643
		Examiner Name	Lynn Anne Bristol
Sheet 5	of 5	Attorney Docket Number	49409-0050 (315804)

OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	68	VENEGAS, et al., "Purification and Immunochemical Characterization of Ascitic Fluid Glycoproteins Containing Certain Tumor-Associated and Blood Group Antigen Markers", <i>Glycoconjugate Journal</i> , 1989, Vol. 6, pp. 511-524.	
	69	VOET et al., <i>Biochemistry</i> , 1990, pp. 1096 and 1098	
	70	VOET et al., <i>Biochemistry</i> , 1990, p. 78	
	71	VOLKMANN, M., et al., "Anti-p53 autoantibodies as serological marker in different tumor-entities", <i>Clinical Chemistry</i> , Volume 41, no. S6 part 2, 1995, pp. S221-S222	
	72	Abstract of VON MENS DORF-POUILLY et al.; <i>Anticancer Research</i> , Nov-Dec. 1997, Vol. 17, page 4184	
	73	VON MENS DORFF-POUILLY, S., "Humoral Immune Response to Polymorphic Epithelial Mucin (MUC-1) in patients with Benign and Malignant Breast Tumours"; <i>European Journal of Cancer</i> , Vol. 32A, No. 8, pp. 1325-1331, 1996	
	74	WOLF, et al., "A Tumour-Associated Antigen from The Pleural Effusion of Patients with Squamous-Cell Carcinoma of Lung", <i>Br. J. Cancer</i> , 1978, Vol. 36, pp. 1046-1052.	
	75	Abstract of YAMAMOTO et al.; <i>Proc. Amer. Soc. Cancer Res.</i> , March 1997, page 564	
	76	YAMAMOTO et al., "L-Myc Overexpression and Detection of Auto-Antibodies Against L-Myc in Both the Serum and Pleural Effusion from a Patient with Non-Small Cell Lung Cancer", <i>Internal Medicine</i> , 1997, Vol. 36, No. 10, pp. 724-727.	
	77	YAMAUCHI, et al., "Autoantibodies to C-MYC Nuclear Protein Products in Autoimmune Disease", 1989, pp. 117-119	
	78	ZISMAN et al.; <i>Journal of Urology</i> , 1995, Vol. 154, pp. 1052-1055	
	79	Definition of "monocyte" in On-line Medical Dictionary downloaded on 2/5/05 from <a href="http://url.cancerweb.ncl.ac.uk">url.cancerweb.ncl.ac.uk</a>	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language translation is attached.